Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed May 5, 2025
- Accession no.
- 0000950170-25-063835
- Filed
- May 5, 2025
- Trade date
- May 1-2, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.84M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2025 | Common Stock | MOption exerciseAcquired | +12,856 | $5.05 | +$64,922.8 | 98,478 | Direct | |
| May 1, 2025 | Common Stock | SSaleDisposed | −12,856 | $71.94F3 | −$924,860.64 | 85,622 | Direct | |
| May 2, 2025 | Common Stock | MOption exerciseAcquired | +26,554 | $5.05 | +$134,097.7 | 112,176 | Direct | |
| May 2, 2025 | Common Stock | SSaleDisposed | −25,847 | $72.21F4 | −$1,866,411.87 | 86,329 | Direct | |
| May 2, 2025 | Common Stock | SSaleDisposed | −707 | $72.98F5 | −$51,596.86 | 85,622 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2025 | Common Stock | MOption exerciseDisposed | −12,856 | $0.00 | $0 | 108,540 | Direct | |
| May 2, 2025 | Common Stock | MOption exerciseDisposed | −26,554 | $0.00 | $0 | 81,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.95 to $73.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.